Quantcast
Last updated on April 18, 2014 at 8:18 EDT

Latest Cell Therapeutics Inc. Stories

2014-03-25 08:37:09

PHOENIX, March 25, 2014 /PRNewswire/ -- Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results. http://photos.prnewswire.com/prnvar/20100419/HKM001LOGO...

2014-03-05 04:22:19

SEATTLE, March 5, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26(th) Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA. The presentation will be webcast live and available for replay from the Cell Therapeutics' website Investors section at www.celltherapeutics.com. About Cell Therapeutics Cell Therapeutics (NASDAQ and MTA:...

2014-03-04 16:25:30

- 2014 Priorities: Complete and Report Top-line Results of First Pacritinib Phase 3 and Drive EU Sales of PIXUVRI - SEATTLE, March 4, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013. "2013 was a transformational year for CTI, as we entered into a worldwide license agreement with Baxter International to develop and commercialize our JAK2/FLT3 inhibitor, pacritinib, achieved...

2014-03-03 04:22:38

- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300...

2014-02-27 04:20:49

- Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy - SEATTLE, Feb. 27, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published...

2014-02-25 04:21:56

- Conference Call and Webcast at 4:30 p.m. Eastern Time - SEATTLE, Feb. 25, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m....

2014-02-03 04:22:24

SEATTLE, Feb. 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that Karen Ignagni has been appointed a Director of CTI, effective immediately. Ms. Ignagni currently serves as President and Chief Executive Officer of America's Health Insurance Plans (AHIP), which is the trade association representing U.S. health plans, serving members that provide healthcare, long-term care, dental and disability benefits to more than 200 million Americans....

2014-01-30 04:21:54

- Trial Sponsored by Cardiff University and Supported by Cancer Research UK - SEATTLE, Jan. 30, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for...

2014-01-28 04:20:52

SEATTLE, Jan. 28, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio(TM) ) as maintenance therapy in ovarian cancer. "Although initial treatment is effective in putting this disease in remission, there is a high relapse rate for patients with ovarian cancer and there...

2014-01-14 04:21:01

SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio. "We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move...